Superworth

Vericel EV/EBIT VCEL

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2021.

Today, Nov 2, 2026
110×
5-year median
200×
Against its 5-year history
16th
percentile: 0 is its lowest day, 100 its highest
5-year range
104× to 498×
Peer median
18.2×

Vericel's EV/EBIT is 110× as of Nov 2, 2026.

That is below its 5-year median of 200×, lower than on 84% of days in the last 5 years.

Over that time it ranged from 104× in May 2026 to 498× in Mar 2025.

The median for 8 biotech stocks of a similar size is 18.2×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far110×104×269×
2025263×251×498×
2024n/m a value too high to mean anything
2023n/m a value too high to mean anything
2022n/m a value too high to mean anything
2021240×240×295×

Against its peers

Companies in Biotechnology nearest Vericel's size, closest first, today.

CompanyEV/EBIT
VCELVericel110×
ADMAAdma Biologics11.3×
MGTXMeiraGTx4.7×
KRYSKrystal Biotech40.1×
RGENRepligen156×
TECHBIO-TECHNE45.0×
HALOHalozyme Therapeutics17.8×
NBIXNeurocrine Biosciences18.6×
EXELExelixis16.8×
Peer median18.2×

Where Vericel ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Vericel

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.